New developments in the treatment of castration resistant prostate cancer.
作者信息
Wadia Roxanne, Petrylak Daniel P
机构信息
Department of Medicine, Smilow Cancer Center, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut, USA.
出版信息
Asian J Androl. 2014 Jul-Aug;16(4):555-60. doi: 10.4103/1008-682X.127824.
Abstract
In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer (CRPC) have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for the development of new drugs to target prostate cancer, and our understanding of genetic mutations may give us new tools with which to more accurately diagnose and be able to predict the course of this heterogeneous disease. This article summarizes the recent advances in the understanding of the development of CRPC, as well as the new drugs and targets, which have evolved from this basic research.
摘要
相似文献
1
New developments in the treatment of castration resistant prostate cancer.
Asian J Androl. 2014 Jul-Aug;16(4):555-60. doi: 10.4103/1008-682X.127824.
2
Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Expert Rev Anticancer Ther. 2017 Jul;17(7):625-633. doi: 10.1080/14737140.2017.1333903. Epub 2017 May 31.
3
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Drug Des Devel Ther. 2015 Jun 29;9:3325-39. doi: 10.2147/DDDT.S69433. eCollection 2015.
4
[New therapies in metastatic castration resistant prostate cancer].
Bull Cancer. 2015 Jun;102(6):501-8. doi: 10.1016/j.bulcan.2015.04.016. Epub 2015 May 26.
5
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
6
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Curr Opin Oncol. 2015 May;27(3):201-8. doi: 10.1097/CCO.0000000000000187.
7
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
Expert Opin Investig Drugs. 2016 Jun;25(6):697-707. doi: 10.1517/13543784.2016.1162784. Epub 2016 Mar 22.
8
[Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Prog Urol. 2013 Oct;23 Suppl 1:S1-8. doi: 10.1016/S1166-7087(13)70040-X.
9
Targeting the mechanisms of progression in castration-resistant prostate cancer.
Eur Urol. 2015 Mar;67(3):480-1. doi: 10.1016/j.eururo.2014.11.024. Epub 2014 Nov 21.
10
Managed care implications in castration-resistant prostate cancer.
Am J Manag Care. 2013 Dec;19(18 Suppl):s376-81.
引用本文的文献
1
From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008-2023).
Am J Mens Health. 2025 May-Jun;19(3):15579883251346819. doi: 10.1177/15579883251346819. Epub 2025 Jun 20.
2
Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats.
Horm Cancer. 2018 Jun;9(3):175-187. doi: 10.1007/s12672-018-0323-z. Epub 2018 Jan 23.
3
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.
Br Dent J. 2015 Jul;218(12):671-7. doi: 10.1038/sj.bdj.2015.439.
4
Global developments in prostate cancer research and clinical practice.
Asian J Androl. 2014 Jul-Aug;16(4):503-4. doi: 10.4103/1008-682X.131073.
本文引用的文献
1
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4.
2
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
J Clin Oncol. 2013 May 10;31(14):1740-7. doi: 10.1200/JCO.2012.46.4149. Epub 2013 Apr 8.
3
Abiraterone in metastatic prostate cancer without previous chemotherapy.
N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10.
4
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18.
5
Increased survival with enzalutamide in prostate cancer after chemotherapy.
N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.
6
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Cancer Immunol Immunother. 2013 Jan;62(1):137-47. doi: 10.1007/s00262-012-1317-2. Epub 2012 Aug 3.
7
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Ann Oncol. 2012 Nov;23(11):2943-2947. doi: 10.1093/annonc/mds119. Epub 2012 Jul 5.
8
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.
9
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Cancer. 2012 Jan 1;118(1):63-71. doi: 10.1002/cncr.26204. Epub 2011 Jul 25.
10
In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Mol Cancer Ther. 2011 Sep;10(9):1728-39. doi: 10.1158/1535-7163.MCT-11-0191. Epub 2011 Jul 12.
Zotero 插件